Literature DB >> 25586140

Enhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound-mediated blood--brain barrier opening in vivo.

Gesthimani Samiotaki1, Camilo Acosta1, Shutao Wang2, Elisa E Konofagou3.   

Abstract

The blood-brain barrier (BBB) constitutes a major obstacle in brain drug delivery. Focused ultrasound (FUS) in conjunction with microbubbles has been shown to open the BBB noninvasively, locally, and transiently to allow large molecules diffusion. Neurturin (NTN), a member of the glial-derived neurotrophic factor (GDNF) family, has been demonstrated to have neuroprotective and regenerative effects on dopaminergic neurons in vivo using invasive drug delivery methods. The brain's ascending nigrostriatal pathway is severely damaged in Parkinson's disease (PD), and therefore the substantia nigra (SN) and striatal caudoputamen (CP) were selected as the target areas. The objective of the study was to investigate whether safe and efficient NTN delivery can be achieved through FUS-induced BBB opening via intravenous administration, and thus trigger the neuroregeneration cascade in the nigrostriatal pathway. After the optimization of FUS parameters and target locations in the murine brain, NTN bioavailability and downstream signaling were detected and characterized through immunostaining. FUS significantly enhanced the delivery of NTN compared with the direct injection technique, whereas triggering of the signaling cascade was detected downstream to the neuronal nuclei. These findings thus indicate the potential of the FUS method to mediate transport of proteins through the blood-brain barrier in a PD animal model.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25586140      PMCID: PMC4420879          DOI: 10.1038/jcbfm.2014.236

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  43 in total

Review 1.  The blood-brain barrier: bottleneck in brain drug development.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

2.  Dynamic study of blood-brain barrier closure after its disruption using ultrasound: a quantitative analysis.

Authors:  Benjamin Marty; Benoit Larrat; Maxime Van Landeghem; Caroline Robic; Philippe Robert; Marc Port; Denis Le Bihan; Mathieu Pernot; Mickael Tanter; Franck Lethimonnier; Sébastien Mériaux
Journal:  J Cereb Blood Flow Metab       Date:  2012-07-18       Impact factor: 6.200

3.  Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

Authors:  Jeffrey H Kordower; Christopher D Herzog; Biplob Dass; Roy A E Bakay; James Stansell; Mehdi Gasmi; Raymond T Bartus
Journal:  Ann Neurol       Date:  2006-12       Impact factor: 10.422

4.  Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

Authors:  Raymond T Bartus; Christopher D Herzog; Yaping Chu; Alistair Wilson; Lamar Brown; Joao Siffert; Eugene M Johnson; C Warren Olanow; Elliott J Mufson; Jeffrey H Kordower
Journal:  Mov Disord       Date:  2010-11-18       Impact factor: 10.338

5.  Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption.

Authors:  Manabu Kinoshita; Nathan McDannold; Ferenc A Jolesz; Kullervo Hynynen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-25       Impact factor: 11.205

6.  Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.

Authors:  Richard Grondin; Zhiming Zhang; Ai Yi; Wayne A Cass; Navin Maswood; Anders H Andersen; Dennis D Elsberry; Michael C Klein; Greg A Gerhardt; Don M Gash
Journal:  Brain       Date:  2002-10       Impact factor: 13.501

7.  Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.

Authors:  Yoshitsugu Oiwa; Ryo Yoshimura; Kunio Nakai; Toru Itakura
Journal:  Brain Res       Date:  2002-08-30       Impact factor: 3.252

8.  Quantitative evaluation of focused ultrasound with a contrast agent on blood-brain barrier disruption.

Authors:  Feng-Yi Yang; Wen-Mei Fu; Rong-Sen Yang; Houng-Chi Liou; Kai-Hsiang Kang; Win-Li Lin
Journal:  Ultrasound Med Biol       Date:  2007-06-11       Impact factor: 2.998

9.  Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys.

Authors:  Navin Maswood; Richard Grondin; Zhiming Zhang; John A Stanford; Stewart P Surgener; Don M Gash; Greg A Gerhardt
Journal:  Neurobiol Aging       Date:  2002 Sep-Oct       Impact factor: 4.673

10.  Noninvasive, transient and selective blood-brain barrier opening in non-human primates in vivo.

Authors:  Fabrice Marquet; Yao-Sheng Tung; Tobias Teichert; Vincent P Ferrera; Elisa E Konofagou
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

View more
  45 in total

Review 1.  Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.

Authors:  Iason T Papademetriou; Tyrone Porter
Journal:  Ther Deliv       Date:  2015-08-25

Review 2.  Blood-brain barrier opening with focused ultrasound in experimental models of Parkinson's disease.

Authors:  Maria Eleni Karakatsani; Javier Blesa; Elisa Evgenia Konofagou
Journal:  Mov Disord       Date:  2019-07-30       Impact factor: 10.338

Review 3.  New horizons for focused ultrasound (FUS) - therapeutic applications in neurodegenerative diseases.

Authors:  Diane B Miller; James P O'Callaghan
Journal:  Metabolism       Date:  2017-01-11       Impact factor: 8.694

4.  Lipid microbubbles as a vehicle for targeted drug delivery using focused ultrasound-induced blood-brain barrier opening.

Authors:  Carlos Sierra; Camilo Acosta; Cherry Chen; Shih-Ying Wu; Maria E Karakatsani; Manuel Bernal; Elisa E Konofagou
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 5.  Advances in acoustic monitoring and control of focused ultrasound-mediated increases in blood-brain barrier permeability.

Authors:  Ryan M Jones; Kullervo Hynynen
Journal:  Br J Radiol       Date:  2019-02-28       Impact factor: 3.039

6.  Focused Ultrasound: An Emerging Therapeutic Modality for Neurologic Disease.

Authors:  Paul S Fishman; Victor Frenkel
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 7.  Image-guided ultrasound phased arrays are a disruptive technology for non-invasive therapy.

Authors:  Kullervo Hynynen; Ryan M Jones
Journal:  Phys Med Biol       Date:  2016-08-05       Impact factor: 3.609

8.  Noninvasive delivery of an α-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound.

Authors:  Kristiana Xhima; Fadl Nabbouh; Kullervo Hynynen; Isabelle Aubert; Anurag Tandon
Journal:  Mov Disord       Date:  2018-09-28       Impact factor: 10.338

Review 9.  Ultrasound Technologies for Imaging and Modulating Neural Activity.

Authors:  Claire Rabut; Sangjin Yoo; Robert C Hurt; Zhiyang Jin; Hongyi Li; Hongsun Guo; Bill Ling; Mikhail G Shapiro
Journal:  Neuron       Date:  2020-10-14       Impact factor: 17.173

Review 10.  Impaired tissue barriers as potential therapeutic targets for Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  Xin Fang
Journal:  Metab Brain Dis       Date:  2018-04-22       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.